Le Lézard
Classified in: Science and technology
Subject: BFA

Stay Better in China: Tell the Beautiful China to the World


NANCHANG, China, Nov. 9, 2024 /PRNewswire/ -- A report from Jiangxi International Communication Center (JXICC): Komurcu Busra, an international student from Nanchang University, talks about her life in China. She felt the simplicity of Chinese countryside and pure beauty of nature here. She wants to tell the beautiful China to the world.

https://www.youtube.com/watch?v=vQGbRJc4ncc

SOURCE Jiangxi International Communication Center(JXICC)


These press releases may also interest you

at 08:00
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
This holiday season, DermRays invites you to redefine the spirit of giving with gifts that bring radiant confidence and timeless beauty. December 9-31, enjoy our exclusive Christmas Season Promotion: $100 OFF all purchases, plus a chance to receive a...

at 07:27
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
The role of governance in local, regional and international efforts to tackle land degradation, drought and desertification, dominated discussions during Governance Day at COP16 in Riyadh on Friday. Proceedings featured major events driving action on...

7 déc 2024
Orca Bio Presents Clinical Results on Use of Orca-Q® without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today presented clinical findings on the use of Orca-Q, its investigational second-generation allogeneic T-cell...

7 déc 2024
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Genmab A/S : Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment...

7 déc 2024
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
?        82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML ? ?        64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of...

7 déc 2024
OpsHub Amplifies its Presence on the Visual Studio (VSTS) Marketplace
OpsHub, a recognized industry leader in Intelligent...

More news about Science and technology...


News published on and distributed by: